RecruitingRecruiting
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
NCT07001956 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Clinical Study on the Treatment of Refractory Moderate - to - Severe Active Rheumatoid Arthritis With UTAA91 Injection
About this study
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with refractory moderate - to - severe active rheumatoid arthritis.
Eligibility criteria
Inclusion Criteria:
* Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.
* Expected survival time of at least 3 months.
* Subjects with refractory moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options.
* Meet the requirements for liver and kidney function, as well as cardiopulmonary function.
* Free from severe psychiatric disorders.
* Able to understand the trial and have signed the informed consent form.
Exclusion Criteria:
* A history of malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years prior to screening.
* Subjects with positive results in virus/syphilis tests.
* Severe cardiac diseases or unstable systemic diseases.
* Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening.
* Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.
* Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening.
* Subjects who participated in other clinical studies within 1 month before screening.
* Other conditions deemed unsuitable for enrollment by the investigator.
Study design
Enrollment target: 24 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-05-30
Estimated completion: 2040-06
Last updated: 2025-07-18
Interventions
Biological: UTAA91 injection
Primary outcomes
- • Adverse events (About 1 year)
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · other
Contacts & investigators
ContactQiubai Li, MD · contact · qiubaili@hust.edu.cn · +8613995671635
All locations (1)
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRecruiting
Wuhan, Hubei, China